252 related articles for article (PubMed ID: 36169649)
1. High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A; Yamada T; Serizawa M; Uehara H; Tanimura K; Okuma Y; Fukuda A; Watanabe S; Nishioka N; Takeda T; Chihara Y; Takemoto S; Harada T; Hiranuma O; Shirai Y; Shukuya T; Nishiyama A; Goto Y; Shiotsu S; Kunimasa K; Morimoto K; Katayama Y; Suda K; Mitsudomi T; Yano S; Kenmotsu H; Takahashi T; Takayama K
Cancer Sci; 2023 Feb; 114(2):606-618. PubMed ID: 36169649
[TBL] [Abstract][Full Text] [Related]
2. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
3. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
4. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
[TBL] [Abstract][Full Text] [Related]
5. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
7. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R; Yamada T; Kita K; Taniguchi H; Arai S; Fukuda K; Terashima M; Ishimura A; Nishiyama A; Tanimoto A; Takeuchi S; Ohtsubo K; Yamashita K; Yamano T; Yoshimura A; Takayama K; Kaira K; Taniguchi Y; Atagi S; Uehara H; Hanayama R; Matsumoto I; Han X; Matsumoto K; Wang W; Suzuki T; Yano S
Nat Commun; 2020 Sep; 11(1):4607. PubMed ID: 32929081
[TBL] [Abstract][Full Text] [Related]
8. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Morimoto K; Yamada T; Sawada R; Azuma K; Goto Y; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Tanaka S; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
Cancer Immunol Immunother; 2023 Jun; 72(6):1699-1707. PubMed ID: 36617602
[TBL] [Abstract][Full Text] [Related]
10. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
11. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
12. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for
Shiozawa T; Numata T; Tamura T; Endo T; Kaburagi T; Yamamoto Y; Yamada H; Kikuchi N; Saito K; Inagaki M; Kurishima K; Funayama Y; Miyazaki K; Koyama N; Furukawa K; Nakamura H; Kikuchi S; Ichimura H; Sato Y; Sekine I; Satoh H; Hizawa N
Anticancer Res; 2022 May; 42(5):2583-2590. PubMed ID: 35489768
[TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R;
Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806
[TBL] [Abstract][Full Text] [Related]
15. Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y; Agemi Y; Shiba A; Ikeda T; Higashi Y; Aga M; Miyazaki K; Taniguchi Y; Misumi Y; Nakamura Y; Shimokawa T; Saigusa Y; Kobayashi N; Okamoto H; Kaneko T
Cancer Med; 2023 Sep; 12(17):17788-17797. PubMed ID: 37548381
[TBL] [Abstract][Full Text] [Related]
16. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
18. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
19. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients
with Advanced EGFR Positive NSCLC and Its Relationship with the
Therapeutic Efficacy of EGFR-TKIs].
Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
[TBL] [Abstract][Full Text] [Related]
20. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
